ABOS
AcumenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The post-earnings company update kept the core bull case intact: ALTITUDE-AD remains on track for a late-2026 readout and the updated cash balance supports execution into early 2027 [#8-K-2026-05-12].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash runway is only guided into early 2027, leaving medium-term financing or dilution risk if catalysts slip.
Momentum
72
Value
42
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.80 · Bull $6.00 · Bear $0.80
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.00
Why
Momentum72 · Δ7d -
Value42 · Δ7d +0.0
Sentiment78 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
72
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
78
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 72.3 / Value 41.9 / Sentiment 77.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$171.18M
Beta
0.24
Shares Out
60.57M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.38
Rev YoY
-
EPS YoY
+11.9%
Gross Margin
-
Op Margin
-
Net Debt
-$142.14M
Current Ratio
6.02
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology